Home-Delivered Meals and Nursing Home Placement Among People With Self-Reported Dementia: A Pilot Pragmatic Clinical Trial.

Importance: Home-delivered meals promote food security and independence among homebound older adults. However, it is unclear which of the 2 predominant modes of meal delivery, daily-delivered vs mailed (or drop-shipped) frozen meals, promotes community living for homebound older adults with dementia. Objective: To assess the risk of nursing home admission within 6 months between homebound individuals receiving daily-delivered vs drop-shipped frozen meals. Design, Setting, and Participants: This pilot, multisite, 2-arm, pragmatic clinical trial included older adults with self-reported dementia on waiting lists for meals at 3 Meals on Wheels (MOW) programs in Texas and Florida between April 7 and October 8, 2021, to assess time to nursing home placement. Interventions: Participants were randomized to receive either meals delivered by an MOW driver or frozen meals that were mailed to participants' homes every 2 weeks. Participants received their assigned intervention for up to 6 months. Main Outcomes and Measures: The primary study outcome was days from randomization to a Minimum Data Set nursing home admission assessment within 6 months. Feasibility of conducting this type of study was examined by tracking enrollment, examining baseline characteristics, monitoring participants' intervention fidelity, measuring the proportion of participants linked with Centers for Medicare & Medicaid Services (CMS) data, and analyzing the primary study outcome. Results: Among 325 eligible participants who were randomized, 243 enrolled in the study (mean [SD] age, 81 [8.0] years; 152 (62.6%) were female): 128 to the daily-delivered meals group and 115 to the drop-shipped frozen meals group; 119 participants (49.0%) lived alone. Among the total participants enrolled, 227 (93.4%) were linked deterministically to their CMS data; probabilistic methods were used to link the remaining 16 participants (6.6%). At 6 months from randomization, 160 participants (65.8%) were still receiving meals, and 25 (10.1%; 95% CI, 6.3%-14.0%) were admitted to a nursing home. After adjusting for sex, race and ethnicity, age, program, and living arrangement and the use of death as a censoring event, the adjusted log hazard ratio of nursing home placement between daily-delivered and drop-shipped frozen meals was -0.67 (95% CI, -1.52 to 0.19). Conclusions and Relevance: This pilot randomized clinical trial demonstrated the feasibility of enrolling participants with self-reported dementia on waiting lists at MOW programs, linking their data, and evaluating outcomes. While this pilot study was not powered to detect meaningful, statistically significant differences in nursing home placement, its feasibility and initial results warrant exploration in a follow-on, adequately powered trial. Trial Registration: ClinicalTrials.gov Identifier: NCT04850781.

Survival and Healthcare Costs with Invasive Mechanical Ventilation versus Noninvasive Ventilation in Patients with Dementia Admitted with Pneumonia and Respiratory Failure.

Rationale: Invasive mechanical ventilation (IMV) may be burdensome for persons with advanced dementia. Research has shown that IMV use in persons with dementia has increased in the United States, Spain, and Canada. Objectives: To compare the outcomes and healthcare costs among hospitalized patients with advanced dementia treated with noninvasive ventilation (NIV) versus IMV. Methods: A retrospective cohort study was conducted among hospitalized patients aged 66 years and older with pneumonia, or septicemia with pneumonia, treated with either NIV or IMV between 2015 and 2017. Persons were included if they had Minimum Data Set (MDS) assessments between 1 and 120 days before hospitalization indicating that they had advanced dementia with four or more impairments in activities of daily living. Propensity-matched analysis was performed using clinical information from the MDS, Chronic Condition Warehouse indicators of chronic disease, and prior use measures. Main outcome measures were survival and healthcare costs up to 1 year after discharge. Results: Among 27,483 hospitalizations between 2015 and 2017, IMV was used in 12.5% and NIV in 8.2%. A propensity-matched model comparing IMV versus NIV using clinical data from the MDS, Chronic Condition Warehouse indicators of chronic diseases, and prior use revealed matches for 96.3% of hospitalizations with the use of IMV. NIV matched cases had a higher 30-day mortality rate compared with IMV cases (58.7% vs. 51.9%, P ⩽ 0.001), but this survival benefit did not persist, as 1-year mortality was slightly higher among subjects with IMV compared with those with NIV (86.5% vs. 85.9%, P > 0.05). One-year healthcare costs after matching were higher among those treated with IMV compared with NIV (mean, $57,122 vs. $33,696; P < 0.001). Conclusions: Among patients with advanced dementia hospitalized with pneumonia or septicemia with pneumonia, improvement in 30-day survival for those treated with IMV compared with NIV must be weighed against lack of 1-year survival benefit and substantially higher costs.